The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis

Documents similaires

• Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
  par: Yunwen Xu, et autres
  Publié: (2025)
• Impact of glucagon‐like peptide‐1 receptor agonism‐based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta‐analysis
  par: Deep Dutta, et autres
  Publié: (2025)
• Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
  par: Frederick Berro Rivera, et autres
  Publié: (2024)
• Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis
  par: Muhammad Aaqib Shamim, et autres
  Publié: (2024)
• Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
  par: Fu‐Shun Yen, et autres
  Publié: (2025)